OREANDA-NEWS  Ministry of Health (MOH) On November 20, Russia was granted permission to use a vaccine for the treatment of melanoma and a peptide vaccine for the treatment of malignant neoplasms. This is reported by TASS with reference to the Minister of Health Mikhail Murashko.

"This is a new generation of antitumor drugs: a therapeutic mRNA—based vaccine and a peptide vaccine," Murashko said.

The minister added that scientists have yet to evaluate the effectiveness and safety of innovative drugs, as this is only the beginning of their use. Therefore, at the moment, vaccines will not be used en masse.

"This technology is not a panacea, but just one of the treatment methods that we are currently developing and implementing," Murashko said.

A personalized neoantigen-specific mRNA vaccine for the treatment of melanoma was developed by the Gamaleya Center and the Blokhin Oncology Center, the manufacturer is the Radiology Center of the Ministry of Health.

A peptide vaccine for the treatment of malignant neoplasms is produced by the Lopukhin Center for Physico-Chemical Medicine (FMBA). It is intended for the treatment of patients with metastatic colorectal cancer.

In addition, the FMBA announced that preclinical studies of the effectiveness of drugs against glioblastoma and melanoma will be completed soon.

Earlier, Russian scientists announced the start of the development of an international code of ethics for geroprotectors, drugs that slow down biological aging and theoretically can increase life expectancy.